Ignite Creation Date:
2024-05-06 @ 7:26 PM
Last Modification Date:
2024-10-26 @ 3:06 PM
Study NCT ID:
NCT06008353
Status:
RECRUITING
Last Update Posted:
2023-10-11
First Post:
2023-03-07
Brief Title:
A Real-World Assessment of the Demographic Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in ES-SCLC in Brazil
Sponsor:
Latin American Cooperative Oncology Group
Organization:
Latin American Cooperative Oncology Group
Study Overview
Official Title:
A Real-World Assessment of the Demographic Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in ES-SCLC in Brazil
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EDUR-BRA
Brief Summary:
The central objective of this study is to characterize the demographic of an ES-SCLC Brazilian cohort treated with durvalumab Secondarily to assess the outcomes of durvalumab-based regimens in 1L treatment of ES-SCLC Brazilian patients from the private health care setting
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| D4191R00053 | OTHER_GRANT | AstraZeneca | None |